Loss of passively acquired maternal antibodies in highly vaccinated populations: An emerging need to define the ontogeny of infant immune responses

Journal of Infectious Diseases

Volumn 208, Issue 1, 2013, Pages 1-3

  Gans, Hayley A ^a   Maldonado, Yvonne A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

MMR vaccine; ontogeny of infant immunity; passive antibodies

Indexed keywords

MATERNAL ANTIBODY; MEASLES MUMPS RUBELLA VACCINE;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIBODY TITER; CELLULAR IMMUNITY; EPIDEMIC; HERD IMMUNITY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INFANT IMMUNITY; INFECTION; MEASLES; MORBIDITY; MORTALITY; NOTE; ONTOGENY; PASSIVE IMMUNIZATION; PLACENTAL TRANSFER; PRIORITY JOURNAL;

MMR VACCINE; ONTOGENY OF INFANT IMMUNITY; PASSIVE-ANTIBODIES;

ANTIBODIES, VIRAL; CHICKENPOX; FEMALE; HUMANS; MEASLES; MEASLES-MUMPS-RUBELLA VACCINE; MUMPS; RUBELLA;

EID: 84878588270     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit144     Document Type: Note

References (40)

1. Goncalves G, Cutts FT, Hills M, Rebelo-Andrade H, Trigo FA, Barros H. Transplacental transfer of measles and total IgG. Epidemiol Infect 1999; 122:273-9.
2. Goncalves G, Nascimento MS, Reu C, Cutts FT. Levels of rubella antibody among vaccinated and unvaccinated Portuguese mothers and their newborns. Vaccine 2006; 24:7142-7.
3. Leineweber B, Grote V, Schaad UB, Heininger U. Transplacentally acquired immunoglobulin G antibodies against measles, mumps, rubella and varicella-zoster virus in preterm and full term newborns. Pediatr Infect Dis J 2004; 23:361-3.
4. Leuridan E, Hens N, Hutse V, Ieven M, Aerts M, Van Damme P. Early waning of maternal measles antibodies in era of measles elimination: longitudinal study. BMJ 2010; 340:c1626.
5. Leuridan E, Van Damme P. Passive transmission and persistence of naturally acquired or vaccine-induced maternal antibodies against measles in newborns. Vaccine 2007; 25:6296-304.
6. Wang Z, Zhang S, Luo C, et al. Transplacentally acquired maternal antibody against hepatitis B surface antigen in infants and its influence on the response to hepatitis B vaccine. PLoS One 2011; 6:e25130.
7. Chan J, Nirwati H, Triasih R, et al. Maternal antibodies to rotavirus: could they interfere with live rotavirus vaccines in developing countries? Vaccine 2011; 29:1242-7.
8. Carson MM, Spady DW, Albrecht P, et al. Measles vaccination of infants in a wellvaccinated population. Pediatr Infect Dis J 1995; 14:17-22.
9. Gans HA, Arvin AM, Galinus J, Logan L, DeHovitz R, Maldonado Y. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 1998; 280:527-32.
10. Hisano M, Yamaguchi K. Usefulness of influenza vaccination during pregnancy to mothers and young infants. Expert Rev Vaccines 2012; 11:903-5.
11. Global reductions in measles mortality 2000-2008 and the risk of measles resurgence. Wkly Epidemiol Rec 2009; 84:509-16.
12. Measles-United States, 2011. Morb Mortal Wkly Rep 2012; 61:253-7.
13. Papania M, Baughman AL, Lee S, et al. Increased susceptibility to measles in infants in the United States. Pediatrics 1999; 104: e59.
14. Yip FY, Papania MJ, Redd SB. Measles outbreak epidemiology in the United States, 1993-2001. J Infect Dis 2004; 189(Suppl 1): S54-60.
15. Lennon JL, Black FL. Maternally derived measles immunity in era of vaccineprotected mothers. J Pediatr 1986; 108: 671-6.
16. Markowitz LE, Albrecht P, Rhodes P, et al. Changing levels of measles antibody titers in women and children in the United States: impact on response to vaccination. Kaiser Permanente Measles Vaccine Trial Team. Pediatrics 1996; 97:53-8.
17. Global measles mortality, 2000-2008. Morb Mortal Wkly Rep 2009; 58:1321-6.
18. Measles imported by returning U.S. travelers aged 6-23 months, 2001-2011. Morb Mortal Wkly Rep 2011; 60:397-400.
19. Gindler J, Tinker S, Markowitz L, Atkinson W, Dales L, Papania MJ. Acute measles mortality in the United States, 1987-2002. J Infect Dis 2004; 189(Suppl 1):S69-77.
20. Gans H, Yasukawa L, Rinki M, et al. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis 2001; 184:817-26.
21. Klinge J, Lugauer S, Korn K, Heininger U, Stehr K. Comparison of immunogenicity and reactogenicity of a measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9-11, 12-14 or 15-17 months of age. Vaccine 2000; 18:3134-40.
22. Khandaker G, Marshall H, Peadon E, et al. Congenital and neonatal varicella: impact of the national varicella vaccination programme in Australia. Arch Dis Child 2011; 96:453-6.
23. Liu L, Johnson HL, Cousens S, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 2012; 379:2151-61.
24. Zarocostas J. Mortality from measles fell by 91% in Africa from 2000 to 2006. BMJ 2007; 335:1173.
25. CDC. Update: Measles-United States, January-July 2008. MMWR 2008; 57:893-6.
26. Dayan GH, Rubin S. Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks? Clin Infect Dis 2008; 47:1458-67.
27. Johnson CE, Nalin DR, Chui LW, Whitwell J, Marusyk RG, Kumar ML. Measles vaccine immunogenicity in 6-versus 15-month-old infants born to mothers in the measles vaccine era. Pediatrics 1994; 93:939-44.
28. Kumar ML, Johnson CE, Chui LW, Whitwell JK, Staehle B, Nalin D. Immune response to measles vaccine in 6-month-old infants of measles seronegative mothers [published erratum appears in Vaccine 1999;17(17):2206]. Vaccine 1998; 16:2047-51.
29. Markowitz LE, Sepulveda J, Diaz-Ortega JL, et al. Immunization of six-month-old infants with different doses of Edmonston-Zagreb and Schwarz measles vaccines [published erratum appears in N Engl J Med 1990; 322(12):863]. N Engl J Med 1990; 322: 580-7.
30. Gans HA, Yasukawa LL, Alderson A, et al. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. J Infect Dis 2004; 190:83-90.
31. Hutchins SS, Dezayas A, Le Blond K, et al. Evaluation of an early two-dose measles vaccination schedule. Am J Epidemiol 2001; 154:1064-71.
32. Aaby P, Andersen M, Sodemann M, Jakobsen M, Gomes J, Fernandes M. Reduced childhood mortality after standard measles vaccination at 4-8 months compared with 9-11 months of age. BMJ 1993; 307:1308-11.
33. Carson MM, Spady DW, Beeler JA, Krezolek MP, Audet S, Pabst HF. Follow-up of infants given measles vaccine at 6 months of age: antibody and CMI responses to MMRII at 15 months of age and antibody levels at 27 months of age. Vaccine 2005; 23: 3247-55.
34. Siegrist C, Barrios C, Martinex X, et al. Influence of maternal antibodies on vaccine responses: inhibition of antibody but not T cell responses allows successful early primeboost strategies in mice. Eur J Immunol 1998; 28:4138-48.
35. Gans HA, Yasukawa LL, Sung P, et al. Measles humoral and cell-mediated immunity in children aged 5-10 years after primary measles immunization administered at 6 or 9 months of age. J Infect Dis 2013; 207:574-82.
36. Kakoulidou M, Ingelman-Sundberg H, Johansson E, et al. Kinetics of antibody and memory B cell responses after MMR immunization in children and young adults. Vaccine 2013; 31:711-7.
37. Gans HA, Maldonado Y, Yasukawa LL, et al. IL-12, IFN-gamma, and T cell proliferation to measles in immunized infants. J Immunol 1999; 162:5569-75.
38. Gans HA, Yasukawa LL, Zhang CZ, et al. Effects of interleukin-12 and interleukin-15 on measles-specific T-cell responses in vaccinated infants. Viral Immunol 2008; 21:163-72.
39. Aaby P, Martins CL, Garly ML, et al. Nonspecific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial. BMJ 2010; 341:c6495.
40. Ota MO, Vekemans J, Schlegel-Haueter SE, et al. Influence of Mycobacterium bovis bacillus Calmette-Guerin on antibody and cytokine responses to human neonatal vaccination. J Immunol 2002; 168:919-25.